Results 21 to 30 of about 230,861 (252)
Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). [PDF]
PLoS Pathogens, 2013 Botulinum neurotoxin serotype A (BoNT/A) causes transient muscle paralysis by entering motor nerve terminals (MNTs) where it cleaves the SNARE protein Synaptosomal-associated protein 25 (SNAP25206) to yield SNAP25197.
Birgitte P S Jacky +12 more
doaj +1 more source
THANATOPHORIC DYSPLASIA: LITERATURE REVIEW AND CLINICAL CASE IN MONOCHORIC DIAMNIOTIC TWINS
Неонатологія, хірургія та перинатальна медицина, 2023 Thanatophoric dysplasia, TD (OMIM: 187600, 87601) belongs to the group of FGFR3 chondrodysplasias and is divided into types I and II. The incidence of TD is approximately 1:20,000-50,000 newborns. TD is usually caused by pathogenic variants in the FGFR3
І. Ластівка +5 more
doaj +1 more source
Fibroblast Growth Factor Receptor 3 Gene: Regulation by Serum Response Factor [PDF]
Molecular Endocrinology, 2004 We have previously identified a cis-acting sequence in the proximal promoter of the fibroblast growth factor receptor 3 (FGFR3) gene that strongly activates transcription in chondrocytic cells. Here we report that the transcriptional activity of this sequence (FRE3) requires serum response factor and its cognate recognition motif, serum response ...
Martina I, Reinhold +2 more
openaire +2 more sources
Failure to diagnose hypochondroplasia by prenatal diagnosis: a case report
BMC Pediatrics, 2023 Background Hypochondroplasia (HCH) is a common nonlethal skeletal dysplasia caused by pathogenic variations in the fibroblast growth factor receptor 3 (FGFR3) gene, and HCH has similar clinical manifestations with achondroplasia (ACH), which can be ...
Hua Xie +4 more
doaj +1 more source
FGFR3 (fibroblast growth factor receptor 3) [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2010 Review on FGFR3 (fibroblast growth factor receptor 3), with data on DNA, on the protein encoded, and where the gene is implicated.
openaire +2 more sources
Journal of Animal Science and Biotechnology, 2012 Background Fibroblast growth factor receptor 3 (FGFR3) inhibits growth-plate chondrocyte proliferation and limits bone elongation. Gain-of-function FGFR3 mutations cause dwarfism, reduced telomerase activity and shorter telomeres in growth plate ...
Smith Logan B +2 more
doaj +1 more source
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours [PDF]
Oncogene, 2001 Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date.
K, Sibley, P, Stern, M A, Knowles
openaire +2 more sources
BMC Genetics, 2008 Background Fibroblast growth factor receptor 3 (FGFR3) is expressed in the growth plate of endochondral bones and serves as a negative regulator of linear bone elongation.
Grossman Deborah I +5 more
doaj +1 more source
Frontiers in Immunology, 2021 In addition to its antimicrobial activity, the skin-derived antimicrobial peptide human β-defensin-3 (hBD-3) promotes keratinocyte proliferation and migration to initiate the wound healing process; however, its effects on fibroblasts, which are the major
Miho Takahashi +18 more
doaj +1 more source
Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. [PDF]
PLoS ONE, 2012 Fibroblast Growth Factor receptor (FGFR) activity plays crucial roles in tumor growth and patient survival. However, FGF (Fibroblast Growth Factor) signaling as a target for cancer therapy has been under-investigated compared to other receptor tyrosine ...
Frédéric Larrieu-Lahargue +6 more
doaj +1 more source